Quick Comparison

ALCARNMN (Nicotinamide Mononucleotide)
Half-Life4-5 hours2-3 minutes in blood (rapidly converted to NAD+). NAD+ half-life: 1-2 hours in tissue
Typical DosageStandard: 500-2000 mg daily in 1-2 doses. For cognitive support: 1000-2000 mg daily. For neuropathy: 1500-3000 mg daily. Take in the morning — may be mildly stimulating.Standard: 250-1000 mg daily. Sublingual may improve bioavailability by bypassing first-pass metabolism. Take in the morning — NAD+ follows circadian rhythm and morning supplementation aligns with natural peaks. Effects build over weeks.
AdministrationOral (capsules, powder). Well-absorbed on an empty stomach.Oral (capsules, powder, sublingual). Sublingual may improve bioavailability. Store in cool, dry place.
Research Papers9 papers10 papers
Categories

Mechanism of Action

ALCAR

ALCAR crosses the blood-brain barrier via the organic cation transporter (OCTN2) more effectively than L-carnitine. In neurons, it is hydrolyzed by carnitine acetyltransferase to donate its acetyl group to coenzyme A, forming acetyl-CoA—which can then be used for acetylcholine synthesis via choline acetyltransferase, effectively providing raw material for the memory neurotransmitter. ALCAR also transports long-chain fatty acids across the inner mitochondrial membrane via the carnitine palmitoyltransferase system for beta-oxidation and ATP production. ALCAR activates nerve growth factor (NGF) signaling, possibly through modulation of NGF receptor (TrkA) expression or downstream MAPK/ERK pathways. It has antioxidant properties, reducing lipid peroxidation in mitochondrial membranes and scavenging free radicals. These mechanisms support cognitive function and neuroprotection.

NMN (Nicotinamide Mononucleotide)

NMN is transported into cells via the Slc12a8 transporter (highly expressed in the small intestine and brain) and converted to NAD+ by nicotinamide mononucleotide adenylyltransferases (NMNAT1 in the nucleus, NMNAT2 in axons/Golgi, NMNAT3 in mitochondria). Elevated NAD+ activates the sirtuin family of NAD+-dependent protein deacetylases: SIRT1 deacetylates PGC-1alpha to promote mitochondrial biogenesis, SIRT3 activates superoxide dismutase 2 (SOD2) and isocitrate dehydrogenase 2 (IDH2) for mitochondrial antioxidant defense, and SIRT6 promotes base excision repair of oxidative DNA damage. NAD+ is also consumed by poly(ADP-ribose) polymerases (PARP1/2) during DNA repair — age-related NAD+ depletion impairs PARP function, allowing DNA damage accumulation. In neurons, NAD+ is required for glycolysis (GAPDH cofactor), the TCA cycle, and Complex I of the electron transport chain, directly fueling the enormous ATP demands of synaptic transmission. NAD+ decline with aging (approximately 50% reduction between ages 40-60) reduces all of these processes simultaneously, creating a cascade of mitochondrial dysfunction, impaired DNA repair, and neuroinflammation that NMN supplementation aims to reverse.

Risks & Safety

ALCAR

Common

Nausea, fishy body odor, restlessness, gastrointestinal discomfort.

Serious

May increase agitation in Alzheimer's patients. TMAO production may be a cardiovascular concern with chronic high doses.

Rare

Seizures in susceptible individuals, increased thyroid activity.

NMN (Nicotinamide Mononucleotide)

Common

Mild flushing, nausea, headache initially.

Serious

Long-term human safety data still limited (first human trials completed 2020-2023). Theoretical concern about promoting cancer growth in existing tumors (NAD+ fuels fast-growing cells).

Rare

Insomnia if taken late.

Full Profiles